An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy

Yuji Mishima, Natsuhiko Sugimura, Yuko Matsumoto-Mishima, Yasuhito Terui, Kengo Takeuchi, Suzuka Asai, Daisuke Ennishi, Hiroaki Asai, Masahiro Yokoyama, Kiyotsugu Kojima, Kiyohiko Hatake

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechanisms remains to be clarified. In addition, there is no established prognostic marker to predict an individual response. This study verified the validity of ex vivo complement-dependent cytotoxicity (CDC) susceptibility as a predictor of pathologic tumor regression in patients undergoing rituximab-containing chemotherapy and examined whether CDC contributes to the mechanism of action of rituximab. Experimental Design: A rapid assay system was established to evaluate the tumoricidal activity of rituximab using a living cell-imaging technique. We analyzed lymph node biopsies obtained from 234 patients with suspected lymphomas and estimated the association between CDC susceptibility and the response to rituximab-containing chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. Results: This study revealed that CDC susceptibility of lymphoma cells freshly obtained from patients was strongly associated with response to rituximab-containing chemotherapy in both diffuse large B-cell lymphoma and follicular lymphoma. This correlation was not apparent in cases that received chemotherapy without rituximab. Conclusions: The system that we have established allows a successful assessment of rituximab-induced CDC and can distinguish cases refractory to rituximab-containing chemotherapy. The association between CDC susceptibility and therapy response suggests that CDC is pivotal in the ability of chemotherapy including rituximab to induce remission.

Original languageEnglish
Pages (from-to)3624-3632
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number10
DOIs
Publication statusPublished - May 15 2009
Externally publishedYes

Fingerprint

Drug Therapy
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma
Rituximab
Non-Hodgkin's Lymphoma
Research Design
Lymph Nodes
Biopsy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. / Mishima, Yuji; Sugimura, Natsuhiko; Matsumoto-Mishima, Yuko; Terui, Yasuhito; Takeuchi, Kengo; Asai, Suzuka; Ennishi, Daisuke; Asai, Hiroaki; Yokoyama, Masahiro; Kojima, Kiyotsugu; Hatake, Kiyohiko.

In: Clinical Cancer Research, Vol. 15, No. 10, 15.05.2009, p. 3624-3632.

Research output: Contribution to journalArticle

Mishima, Y, Sugimura, N, Matsumoto-Mishima, Y, Terui, Y, Takeuchi, K, Asai, S, Ennishi, D, Asai, H, Yokoyama, M, Kojima, K & Hatake, K 2009, 'An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy', Clinical Cancer Research, vol. 15, no. 10, pp. 3624-3632. https://doi.org/10.1158/1078-0432.CCR-08-1536
Mishima, Yuji ; Sugimura, Natsuhiko ; Matsumoto-Mishima, Yuko ; Terui, Yasuhito ; Takeuchi, Kengo ; Asai, Suzuka ; Ennishi, Daisuke ; Asai, Hiroaki ; Yokoyama, Masahiro ; Kojima, Kiyotsugu ; Hatake, Kiyohiko. / An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 10. pp. 3624-3632.
@article{53c1fee167894b5caf249fa898599afb,
title = "An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy",
abstract = "Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechanisms remains to be clarified. In addition, there is no established prognostic marker to predict an individual response. This study verified the validity of ex vivo complement-dependent cytotoxicity (CDC) susceptibility as a predictor of pathologic tumor regression in patients undergoing rituximab-containing chemotherapy and examined whether CDC contributes to the mechanism of action of rituximab. Experimental Design: A rapid assay system was established to evaluate the tumoricidal activity of rituximab using a living cell-imaging technique. We analyzed lymph node biopsies obtained from 234 patients with suspected lymphomas and estimated the association between CDC susceptibility and the response to rituximab-containing chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. Results: This study revealed that CDC susceptibility of lymphoma cells freshly obtained from patients was strongly associated with response to rituximab-containing chemotherapy in both diffuse large B-cell lymphoma and follicular lymphoma. This correlation was not apparent in cases that received chemotherapy without rituximab. Conclusions: The system that we have established allows a successful assessment of rituximab-induced CDC and can distinguish cases refractory to rituximab-containing chemotherapy. The association between CDC susceptibility and therapy response suggests that CDC is pivotal in the ability of chemotherapy including rituximab to induce remission.",
author = "Yuji Mishima and Natsuhiko Sugimura and Yuko Matsumoto-Mishima and Yasuhito Terui and Kengo Takeuchi and Suzuka Asai and Daisuke Ennishi and Hiroaki Asai and Masahiro Yokoyama and Kiyotsugu Kojima and Kiyohiko Hatake",
year = "2009",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1536",
language = "English",
volume = "15",
pages = "3624--3632",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy

AU - Mishima, Yuji

AU - Sugimura, Natsuhiko

AU - Matsumoto-Mishima, Yuko

AU - Terui, Yasuhito

AU - Takeuchi, Kengo

AU - Asai, Suzuka

AU - Ennishi, Daisuke

AU - Asai, Hiroaki

AU - Yokoyama, Masahiro

AU - Kojima, Kiyotsugu

AU - Hatake, Kiyohiko

PY - 2009/5/15

Y1 - 2009/5/15

N2 - Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechanisms remains to be clarified. In addition, there is no established prognostic marker to predict an individual response. This study verified the validity of ex vivo complement-dependent cytotoxicity (CDC) susceptibility as a predictor of pathologic tumor regression in patients undergoing rituximab-containing chemotherapy and examined whether CDC contributes to the mechanism of action of rituximab. Experimental Design: A rapid assay system was established to evaluate the tumoricidal activity of rituximab using a living cell-imaging technique. We analyzed lymph node biopsies obtained from 234 patients with suspected lymphomas and estimated the association between CDC susceptibility and the response to rituximab-containing chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. Results: This study revealed that CDC susceptibility of lymphoma cells freshly obtained from patients was strongly associated with response to rituximab-containing chemotherapy in both diffuse large B-cell lymphoma and follicular lymphoma. This correlation was not apparent in cases that received chemotherapy without rituximab. Conclusions: The system that we have established allows a successful assessment of rituximab-induced CDC and can distinguish cases refractory to rituximab-containing chemotherapy. The association between CDC susceptibility and therapy response suggests that CDC is pivotal in the ability of chemotherapy including rituximab to induce remission.

AB - Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechanisms remains to be clarified. In addition, there is no established prognostic marker to predict an individual response. This study verified the validity of ex vivo complement-dependent cytotoxicity (CDC) susceptibility as a predictor of pathologic tumor regression in patients undergoing rituximab-containing chemotherapy and examined whether CDC contributes to the mechanism of action of rituximab. Experimental Design: A rapid assay system was established to evaluate the tumoricidal activity of rituximab using a living cell-imaging technique. We analyzed lymph node biopsies obtained from 234 patients with suspected lymphomas and estimated the association between CDC susceptibility and the response to rituximab-containing chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. Results: This study revealed that CDC susceptibility of lymphoma cells freshly obtained from patients was strongly associated with response to rituximab-containing chemotherapy in both diffuse large B-cell lymphoma and follicular lymphoma. This correlation was not apparent in cases that received chemotherapy without rituximab. Conclusions: The system that we have established allows a successful assessment of rituximab-induced CDC and can distinguish cases refractory to rituximab-containing chemotherapy. The association between CDC susceptibility and therapy response suggests that CDC is pivotal in the ability of chemotherapy including rituximab to induce remission.

UR - http://www.scopus.com/inward/record.url?scp=66149185427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149185427&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1536

DO - 10.1158/1078-0432.CCR-08-1536

M3 - Article

VL - 15

SP - 3624

EP - 3632

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -